Business Context and Reporting Period
This Form 8-K filing by Tocagen Inc. (not Forte Biosciences, Inc., as indicated in the metadata) reports on the results of its 2018 Annual Meeting of Stockholders held on June 21, 2018. The company is incorporated in Delaware and is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
As of the record date (April 23, 2018), 19,912,143 shares were outstanding. Approximately 77.7% of shares were present at the meeting. Two proposals were voted upon:
- Proposal 1: Election of Directors
- Thomas E. Darcy: Elected (8,440,351 For; 864,101 Withheld).
- Harry E. Gruber, M.D.: Elected (8,416,328 For; 888,124 Withheld).
- Paul Schimmel, Ph.D.: Elected (5,628,287 For; 3,676,165 Withheld). Note: Dr. Schimmel received a significantly higher number of withheld votes compared to the other nominees.
- Proposal 2: Ratification of Auditors
- Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
- Votes For: 14,396,230
- Votes Against: 558,772
- Abstention: 507,398
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the submission of matters to a vote of security holders.
Important Facts for Investors to Verify
- Verify the discrepancy between the metadata company name ("Forte Biosciences, Inc.") and the actual registrant in the filing ("Tocagen Inc.").
- Review the voting results for Paul Schimmel, Ph.D., who received a notably higher percentage of withheld votes compared to the other director nominees.
- Confirm the appointment of Ernst & Young LLP as the auditor for the fiscal year ending December 31, 2018.
- Note that this filing contains no financial data; refer to the company's 10-K or 10-Q for financial metrics.